EndoChoice
Alpharetta
About EndoChoice
EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $112.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2015)
- Ticker: nyse:GI
- Website: endochoice.com
- Phone: +1-7709626981
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/endochoice-3112121 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.